Coagulation Factors and the Future of Rare Disease Management

أضاف وظيفة جديدة Autres

2026-02-05 13:27:58

When you look at the sheer numbers, the management of Hemophilia and other bleeding disorders is a high-value pillar of the Blood Plasma Derivatives Market. In 2026, while recombinant (synthetic) factors have taken a significant market share, plasma-derived Factor VIII and Factor IX remain essential for patients who develop inhibitors or require a full-spectrum von Willebrand factor. The US...

0 التعليقات 0 المشاركات 15 مشاهدة 0 معاينة